Changes in fecal microbiota with CFTR modulator therapy: A pilot study
| Autor: | Sharon McNamara, Hillary S. Hayden, Edward F. McKone, Anina Ratjen, Moira L. Aitken, L. Nay, Eli J. Weiss, B. Grogan, S. Carter, Rosenfeld, Anh T. Vo, Lucas R. Hoffman, Pradeep K. Singh, Parsek, S.L. Durfey, Charles E. Pope |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Adult medicine.medical_specialty Malabsorption Adolescent Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Pilot Projects Quinolones Aminophenols Gastroenterology Cystic fibrosis Article Ivacaftor 03 medical and health sciences chemistry.chemical_compound Feces Young Adult fluids and secretions 0302 clinical medicine Internal medicine Medicine Humans Microbiome Child Chloride Channel Agonists business.industry Microbiota Lumacaftor medicine.disease Anti-Bacterial Agents 030104 developmental biology 030228 respiratory system chemistry Pediatrics Perinatology and Child Health Cohort Exocrine Pancreatic Insufficiency business Dysbiosis medicine.drug |
| Zdroj: | J Cyst Fibros |
| ISSN: | 1873-5010 |
| Popis: | Studies have demonstrated that people with CF with pancreatic insufficiency (PI) have fecal dysbioses. Evidence suggests the causes of these dysbioses are multifactorial, and that important drivers include antibiotic exposure, dietary intake, and CF gastrointestinal tract dysfunction, including nutrient malabsorption. In this pilot study, we tested whether initiation of the CFTR modulator treatments ivacaftor (in a cohort of pancreatic sufficient (PS) people with CF and an R117H CFTR variant) or lumacaftor/ivacaftor (in a cohort of PI people with CF and an F508del variant) changed fecal measures of malabsorption or fecal microbiomes. While we identified no statistically significant fecal changes with either treatment, we detected trends in the PI cohort when initiating lumacaftor/ivacaftor towards decreased fecal fat content and towards fecal microbiomes that more closely resembled the fecal microbiota of people without PI. While these findings support a model in which nutrient malabsorption resulting from CF-induced PI drives fecal dysbiosis, they must be validated in future, larger studies of fecal microbiome and malabsorption outcomes with highly effective CFTR modulator therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect